Impact of body weight on efficacy of tildrakizumab in moderate to severe plaque psoriasis - 22/08/19
Craig Leonardi, Central Dermatology and Saint Louis University School of Medicine, St. Louis, MO; Alan M. Menter, Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, TX; Zoe Draelos, Dermatology Consulting Services, High Point, NC; Jayme Heim, West Michigan Dermatology, Holland, MI; Jeff Parno, Sun Pharmaceutical Industries, Inc, Princeton, NJ; Alan M. Mendelsohn, Sun Pharmaceutical Industries, Inc, Princeton, NJ; Stephen J Rozzo, Sun Pharmaceutical Industries, Inc, Princeton, NJ; Christopher E.M. Griffiths, Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, UK
Le texte complet de cet article est disponible en PDF. Supported by Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Kenilworth, NJ; analyses were funded by Sun Pharmaceutical Industries, Inc, Princeton, NJ. Editorial support was provided by JK Associates. |
Vol 81 - N° 4S1
P. AB76 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?